Filing Flows › Ovid Therapeutics (OVID) › Stock forecast & fair value
Ovid Therapeutics (OVID) stock forecast and price target
Ovid Therapeutics (OVID) trades at $2.85. 10 analysts' median price target is $6.00 (+111%), from $4.00 to $9.00.
Ovid Therapeutics' latest quarter
Ovid Therapeutics, Q2 2026: revenue $733K (-88% year over year), net loss $15.0M, operating cash flow −$17.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for OVID stock?
The median of 10 analysts' 12-month targets is $6.00, +111% from $2.85; the range is $4.00 to $9.00. The average rating is strong buy.
Does Ovid Therapeutics usually beat earnings estimates?
It beat the consensus EPS estimate in 50% of the quarters on record.
Is OVID stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.